Altre lingue MIRA Pharmaceuticals, Inc.

Azioni

MIRA

US60458C1045

Tempo differito Nasdaq Altri mercati azionari 20:27:19 21/05/2024			Variaz. 5gg	Var. 1 gen.
0,8597 ^USD	+1,14%		+15,67%	-18,67%

13/05	MIRA Pharmaceuticals, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
02/04	Mira Pharmaceuticals, Inc. annuncia risultati preclinici incoraggianti che fanno avanzare Ketamir-2 verso la potenziale presentazione IND a fine anno	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog	14:46
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog	20/05
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission	02/04
Mira Pharmaceuticals, Inc. Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission	02/04
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor	21/03
Mira Pharmaceuticals Inc. Announces Appointment of Itzchak Angel as Chief Scientific Advisor	21/03
MIRA Pharmaceuticals, Inc. Announces Management Changes	13/03
MIRA Pharmaceuticals, Inc. Provides Updated Information Regarding the Patented, Pre-Clinical Drug Candidate Molecule Known as Mira1a	07/03
MIRA Pharmaceuticals Provides Corporate Update	05/02
Certain Stock Options of MIRA Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-JAN-2024.	30/01
Certain Common Stock of MIRA Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-JAN-2024.	30/01
Certain Warrants of MIRA Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-JAN-2024.	30/01
MIRA Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis from the Board of Directors and as Part-Time General Counsel	17/01
MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations	04/12
MIRA Pharmaceuticals, Inc. Releases Breakthrough Data from Artificial Intelligence Simulations	04/12
MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%	29/11
MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time	21/11
MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a	21/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue MIRA Pharmaceuticals, Inc.

Azioni

MIRA

US60458C1045

Altre lingue

Filtri